Join to View Full Profile
4701 Ogletown Stanton RdHelen F Graham Cancer CenterNewark, DE 19713
Phone+1 302-623-4205
Fax+1 215-955-2340
Dr. Boman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1980 - 1982- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1977 - 1980
University of Minnesota Medical SchoolClass of 1976
Certifications & Licensure
DC State Medical License 1983 - Present
PA State Medical License 1998 - 2026
DE State Medical License 2007 - 2025
MD State Medical License 1983 - 2020
IA State Medical License 1996 - 2000
MN State Medical License 1978 - 1987
TX State Medical License 1985 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Publications & Presentations
PubMed
- The Significance of Aldehyde Dehydrogenase 1 in Cancers.Anh L Nguyen, Caroline O B Facey, Bruce M Boman
International Journal of Molecular Sciences. 2024-12-30 - 1 citationsThe Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies.Anh L Nguyen, Caroline O B Facey, Bruce M Boman
Cancers. 2024-12-30 - 2 citationsLinks WNT and Retinoic Acid Signaling: A Target to Differentiate ALDH+ Stem Cells in-Mutant CRC.Caroline O B Facey, Victoria O Hunsu, Chi Zhang, Brian Osmond, Lynn M Opdenaker
Cancers. 2024-01-07
Journal Articles
- The Anti-Cancer Effect of Retinoic Acid Signaling in CRC Occurs via Decreased Growth of ALDH+ Colon Cancer Stem Cells and Increased Differentiation of Stem CellsBruce Boman, MD, Oncotarget
Press Mentions
ChristianaCare Research May Result in 'More Precise' Advanced Colorectal Cancer TreatmentApril 5th, 2023- Scientists Discover Second Key Pathway in Colon Cancer Stem Cell GrowthOctober 29th, 2020
Key Signaling Pathway Could Lead to New Targets in Colorectal CancerDecember 20th, 2018
Grant Support
- AP4 Center For Studies On Hereditary Colorectal CancerNational Cancer Institute2004
- Proteomic Analyses For GI Stem Cell Markers &MechanismsNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
- Markers For Stem Cell-Like Colonic Crypt Base CellsNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
- Characterizing Murine GI Stem Cells: New Molecular ToolsNational Cancer Institute2003–2004
- Core--Gastrointestinal CancerNational Cancer Institute2001–2002
- Approach For Colon Cancer Therapy Using APC PeptidesNational Cancer Institute1996–1998
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
